95 related articles for article (PubMed ID: 28857255)
1. Efficacy of a concomitant elemental diet to reduce the loss of response to adalimumab in patients with intractable Crohn's disease.
Sugita N; Watanabe K; Kamata N; Yukawa T; Otani K; Hosomi S; Nagami Y; Tanaka F; Taira K; Yamagami H; Tanigawa T; Shiba M; Watanabe T; Tominaga K; Kabata D; Shintani A; Arakawa T; Fujiwara Y
J Gastroenterol Hepatol; 2018 Mar; 33(3):631-637. PubMed ID: 28857255
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of infliximab after loss of response of/intolerance to adalimumab in pediatric Crohn's disease: A retrospective multicenter cohort study of the "GETAID pédiatrique".
Lecoutour A; Dupont C; Caldari D; Dumant C; Vanrenterghem A; Ruiz M; Duclaux-Loras R; Berthet S; Dimitrov G; Lacroix D; Duvant P; Roman C; Wagner AC; Bourmaud A; Viala J; Ruemmele FM; Pigneur B;
J Pediatr Gastroenterol Nutr; 2024 May; 78(5):1116-1125. PubMed ID: 38314896
[TBL] [Abstract][Full Text] [Related]
3. No Correlation between Anti-drug Antibodies and Therapeutic Response in Tunisian Patients with Chronic Inflammatory Diseases Treated by TNF Blockers.
Bouden S; Laadhar L; Soua J; Ben Messaoud M; Rouached L; Ayadi I; Saidane O; Ben Tekaya A; Mahmoud I; Rekik S; Srairi HS; Tekaya R; Bellakhal S; Fekih M; Abdelmoula L; Kallel M
Curr Rheumatol Rev; 2024; 20(4):435-443. PubMed ID: 38314598
[TBL] [Abstract][Full Text] [Related]
4. Superior Efficacy of Infliximab Versus Adalimumab for First-Line Treatment of Crohn's Perianal Fistulae.
Maas L; Gao R; Cusumano V; Spartz E; Chowdhury R; Krishna M; Lazarev M; Melia J; Selaru F; Sharma S; Limketkai B; Parian A
Dig Dis Sci; 2023 Oct; 68(10):3994-4000. PubMed ID: 37540392
[TBL] [Abstract][Full Text] [Related]
5. Adalimumab vs Infliximab in Luminal Pediatric Crohn's Disease: Comparable Outcomes in a Prospective Multicenter Cohort Study.
deBruyn JC; Huynh HQ; Griffiths AM; Jacobson K; Mack D; Deslandres C; El-Matary W; Otley AR; Church PC; Lawrence S; Wine E; Sherlock M; Critch J; Benchimol EI; Jantchou P; Rashid M; Carroll MW; Bax K; Ricciuto A; Carman N; Walters TD;
Am J Gastroenterol; 2024 Mar; 119(3):565-575. PubMed ID: 37787642
[TBL] [Abstract][Full Text] [Related]
6. Immunomodulator comedication promotes the reversal of anti-drug antibody-mediated loss of response to anti-TNF therapy in inflammatory bowel disease.
Stallhofer J; Guse J; Kesselmeier M; Grunert PC; Lange K; Stalmann R; Eckardt V; Stallmach A
Int J Colorectal Dis; 2023 Feb; 38(1):54. PubMed ID: 36840779
[TBL] [Abstract][Full Text] [Related]
7. High Body Mass Index and Response to Anti-Tumor Necrosis Factor Therapy in Pediatric Crohn's Disease.
Ebach DR; Jester TW; Galanko JA; Firestine AM; Ammoury R; Cabrera J; Bass J; Minar P; Olano K; Margolis P; Sandberg K; Linnville TM; Kaplan J; Pitch L; Steiner SJ; Bass D; Moses J; Adler J; Gulati AS; Wali P; Pashankar D; Ivanova A; Herfarth H; Wohl DA; Benkov KJ; Strople J; Sullivan J; Tung J; Molle-Rios Z; Saeed SA; Bousvaros A; Kappelman MD
Am J Gastroenterol; 2024 Jun; 119(6):1110-1116. PubMed ID: 38445644
[TBL] [Abstract][Full Text] [Related]
8. Development and validation of a novel therapeutic drug monitoring-based nomogram for prediction of primary endoscopic response to anti-TNF therapy in active Crohn's disease.
Chen L; Kang D; Fang L; Sun M; Li M; Zhou G; Xu C; Pang Z; Ye Y; Feng B; Wu H; Lin J; Ding B; Liu C; Shi Y; Liu Z
Therap Adv Gastroenterol; 2024; 17():17562848241256237. PubMed ID: 38827646
[TBL] [Abstract][Full Text] [Related]
9. Adalimumab in Biologic-naïve Patients With Crohn's Disease After Resolution of an Intra-abdominal Abscess: A Prospective Study From the GETAID.
Bouhnik Y; Pineton de Chambrun G; Lambert J; Nachury M; Seksik P; Altwegg R; Vuitton L; Stefanescu C; Nancey S; Aubourg A; Serrero M; Filippi J; Desseaux K; Viennot S; Abitbol V; Boualit M; Bourreille A; Giletta C; Buisson A; Roblin X; Dib N; Malamut G; Amiot A; Fumery M; Louis E; Elgharabawy Y; Peyrin-Biroulet L;
Clin Gastroenterol Hepatol; 2023 Dec; 21(13):3365-3378.e5. PubMed ID: 36731588
[TBL] [Abstract][Full Text] [Related]
10. Adalimumab Drug Levels at Secondary Loss of Response Do Not Predict Response to Dose-intensification in Crohn's Disease: A Retrospective, International Multicenter Study.
Little RD; Swaine A; Reynolds R; Gibson DJ; Barrau M; D'Errico F; Hampal R; Sparrow MP; Roblin X; Irving PM; Ward MG
Inflamm Bowel Dis; 2023 Nov; ():. PubMed ID: 37951220
[TBL] [Abstract][Full Text] [Related]
11. Antibiotics influence the risk of anti-drug antibody formation during anti-TNF therapy in Chinese inflammatory bowel disease patients.
Sun M; Ju J; Xu H; Luo M; Li Z; Wang Y
Front Pharmacol; 2024; 15():1360835. PubMed ID: 38655181
[No Abstract] [Full Text] [Related]
12. Safety profile of biologic therapy in Polish paediatric patients with Crohn's disease.
Szymanska E; Dadalski M; Oracz G; Kierkus J
Prz Gastroenterol; 2015; 10(3):164-8. PubMed ID: 26516383
[TBL] [Abstract][Full Text] [Related]
13. A Prediction Model for Successful Increase of Adalimumab Dose Intervals in Patients with Crohn's Disease: Secondary Analysis of the Pragmatic Open-Label Randomised Controlled Non-inferiority LADI Trial.
van Linschoten RCA; Jansen FM; Pauwels RWM; Smits LJT; Atsma F; Kievit W; de Jong DJ; de Vries AC; Boekema PJ; West RL; Bodelier AGL; Gisbertz IAM; Wolfhagen FHJ; Römkens TEH; Lutgens MWMD; van Bodegraven AA; Oldenburg B; Pierik MJ; Russel MGVM; de Boer NK; Mallant-Hent RC; Ter Borg PCJ; van der Meulen-de Jong AE; Jansen JM; Jansen SV; Tan ACITL; van der Woude CJ; Hoentjen F;
Dig Dis Sci; 2024 Jun; 69(6):2165-2174. PubMed ID: 38594435
[TBL] [Abstract][Full Text] [Related]
14. MIF Variant rs755622 Is Associated with Severe Crohn's Disease and Better Response to Anti-TNF Adalimumab Therapy.
Jezernik G; Gorenjak M; Potočnik U
Genes (Basel); 2023 Feb; 14(2):. PubMed ID: 36833379
[TBL] [Abstract][Full Text] [Related]
15. Sarcopenia assessed by computed tomography or magnetic resonance imaging is associated with the loss of response to biologic therapies in adult patients with Crohn's disease.
Liu J; Tang H; Lin T; Wang J; Cui W; Xie C; Wang Z; Chen Y; Chen X
Clin Transl Sci; 2023 Nov; 16(11):2209-2221. PubMed ID: 37621024
[TBL] [Abstract][Full Text] [Related]
16. Positive antiphospholipid antibodies and pulmonary embolism in a patient with adalimumab-induced lupus.
Uehara M; Matsushita S; Aochi S; Yamamoto M
Mod Rheumatol Case Rep; 2023 Jan; 7(1):68-73. PubMed ID: 36208152
[TBL] [Abstract][Full Text] [Related]
17. Granulomas Galore: Concomitant Granulomatous Infections in a Patient With Crohn's Disease.
Gianarakis M; Gianarakis A; Ahmed S; Pueringer J; Ranasinghe U
Cureus; 2024 Feb; 16(2):e54225. PubMed ID: 38496097
[TBL] [Abstract][Full Text] [Related]
18. Molecular docking analysis of natural compounds as TNF-α inhibitors for Crohn's disease management.
Moawadh MS
Bioinformation; 2023; 19(6):716-720. PubMed ID: 37885792
[TBL] [Abstract][Full Text] [Related]
19. ADA-2 gene mutation in a Crohn's disease patient without response to therapy.
Yılmaz EY; Eruzun H; Küçükdemirci Ö; Demiröz H; Altundağ E; Bektaş A
J Gastrointestin Liver Dis; 2024 Mar; 33(1):134-135. PubMed ID: 38554426
[No Abstract] [Full Text] [Related]
20. Safety Considerations with the Use of Corticosteroids and Biologic Therapies in Mild-to-Moderate Ulcerative Colitis.
Cross RK
Inflamm Bowel Dis; 2017 Oct; 23(10):1689-1701. PubMed ID: 28906290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
